Clinical benefits of PD-1/PD-L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and meta-analysis

被引：0

作者：

Quan Rao

Min Li

Wei Xu

Kai Pang

XiaoBo Guo

Dong Wang

Jun Liu

Wei Guo

ZhongTao Zhang

机构：

[1] Capital Medical University,Department of General Surgery, Beijing Friendship Hospital

[2] Beijing Key Laboratory of Cancer Invasion and Metastasis Research and National Clinical Research Center for Digestive Diseases,Clinical Epidemiology and EBM Unit, National Clinical Research Center for Digestive Disease, Beijing Friendship Hospital

[3] Capital Medical University,Department of Vascular Surgery, Beijing Friendship Hospital

[4] Capital Medical University,undefined

来源：

Hepatology International | 2020年 / 14卷

关键词：

PD-1; PD-L1; Monoclonal antibody; Nivolumab; Pembrolizumab; Anti-VEGF agent; Objective response rate; Disease control rate; Overall survival; Progression-free survival; Adverse event; Meta-analysis;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：765 / 775

页数：10

共 50 条

[21] PD-L1/PD-1 In Hepatocellular Carcinoma: An Institutional Review
Poveda, Julio
Duarte, Melissa
Jones, Patricia Denise
Chowdhury, Aneesa
Brown, Kevin
Garcia-Buitrago, Monica
[J]. MODERN PATHOLOGY, 2019, 32
[22] Association of PD-L1 expression with survival benefit from PD-1/PD-L1 inhibitors in advanced cancer: Systematic review and meta-analysis of phase III randomized clinical trials
Kuang, Xiaohong
Xu, Run
Li, Jian
[J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2024, 198
[23] Hepatotoxicity in patients with solid tumors treated with PD-1/PD-L1 inhibitors alone, PD-1/PD-L1 inhibitors plus chemotherapy, or chemotherapy alone: systematic review and meta-analysis
Xiaodi Guo
Wendong Li
Jiexuan Hu
Emily C. Zhu
Qiang Su
[J]. European Journal of Clinical Pharmacology, 2020, 76 : 1345 - 1354
[24] Hepatotoxicity in patients with solid tumors treated with PD-1/PD-L1 inhibitors alone, PD-1/PD-L1 inhibitors plus chemotherapy, or chemotherapy alone: systematic review and meta-analysis
Guo, Xiaodi
Li, Wendong
Hu, Jiexuan
Zhu, Emily C.
Su, Qiang
[J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 76 (10) : 1345 - 1354
[25] Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials A Systematic Review and Meta-analysis
Wang, Yucai
Zhou, Shouhao
Yang, Fang
Qi, Xinyue
Wang, Xin
Guan, Xiaoxiang
Shen, Chan
Duma, Narjust
Aguilera, Jesus Vera
Chintakuntlawar, Ashish
Price, Katharine A.
Molina, Julian R.
Pagliaro, Lance C.
Halfdanarson, Thorvardur R.
Grothey, Axel
Markovic, Svetomir N.
Nowakowski, Grzegorz S.
Ansel, Stephen M.
Wang, Michael L.
[J]. JAMA ONCOLOGY, 2019, 5 (07) : 1008 - 1019
[26] Neoadjuvant PD-1/PD-L1 Inhibitors for Resectable Head and Neck Cancer A Systematic Review and Meta-analysis
Masarwy, Razan
Kampel, Liyona
Horowitz, Gilad
Gutfeld, Orit
Muhanna, Nidal
[J]. JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2021, 147 (10) : 871 - 878
[27] Treatment-Related Adverse Events with PD-1 or PD-L1 Inhibitors: A Systematic Review and Meta-Analysis
Zhang, Yixi
La, Bin
Liang, Baosheng
Gu, Yangchun
[J]. LIFE-BASEL, 2021, 11 (11):
[28] The effects and safety of PD-1/PD-L1 inhibitors on head and neck cancer: A systematic review and meta-analysis
Wang, Bi-Cheng
Cao, Ru-Bo
Li, Pin-Dong
Fu, Chen
[J]. CANCER MEDICINE, 2019, 8 (13): : 5969 - 5978
[29] Comparative Safety of PD-1/PD-L1 Inhibitors for Cancer Patients: Systematic Review and Network Meta-Analysis
Huang, Ya-Fang
Xie, Wen-Jie
Fan, Hai-Yu
Du, Juan
[J]. FRONTIERS IN ONCOLOGY, 2019, 9
[30] Effectiveness and safety of PD-1/PD-L1 inhibitors in the treatment of solid tumors: a systematic review and meta-analysis
Wang, Xiaohui
Bao, Zhengqiang
Zhang, Xiaoju
Li, Fei
Lai, Tianwen
Cao, Chao
Chen, Zhihua
Li, Wen
Shen, Huahao
Ying, Songmin
[J]. ONCOTARGET, 2017, 8 (35) : 59901 - 59914

← 1 2 3 4 5 →